Published in Anticancer Drugs on April 01, 2001
Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm (2008) 7.67
HPMA copolymers: origins, early developments, present, and future. Adv Drug Deliv Rev (2009) 2.13
Overcoming multidrug resistance of small-molecule therapeutics through conjugation with releasable octaarginine transporters. Proc Natl Acad Sci U S A (2008) 1.71
Professor Tom Connors and the development of novel cancer therapies by the Phase I/II Clinical Trials Committee of Cancer Research UK. Br J Cancer (2003) 1.46
Polymer-drug conjugates: recent development in clinical oncology. Adv Drug Deliv Rev (2008) 1.43
Recent trends in targeted anticancer prodrug and conjugate design. Curr Med Chem (2008) 1.33
Enabling individualized therapy through nanotechnology. Pharmacol Res (2010) 1.28
Polymer-drug conjugates: origins, progress to date and future directions. Adv Drug Deliv Rev (2012) 1.28
Polymeric nanomedicine for cancer MR imaging and drug delivery. Chem Commun (Camb) (2009) 1.24
Interactions of nanomaterials and biological systems: Implications to personalized nanomedicine. Adv Drug Deliv Rev (2012) 1.18
Engineered polymers for advanced drug delivery. Eur J Pharm Biopharm (2008) 1.17
Paclitaxel Nano-Delivery Systems: A Comprehensive Review. J Nanomed Nanotechnol (2013) 1.16
Effect of intratumoral injection on the biodistribution and the therapeutic potential of HPMA copolymer-based drug delivery systems. Neoplasia (2006) 1.11
Polymeric conjugates for drug delivery. Chem Mater (2012) 1.06
A phase I and pharmacokinetic study of MAG-CPT, a water-soluble polymer conjugate of camptothecin. Br J Cancer (2002) 1.05
Advances of cancer therapy by nanotechnology. Cancer Res Treat (2009) 1.01
Integrin Targeted MR Imaging. Theranostics (2011) 1.00
Endocytic uptake of a large array of HPMA copolymers: Elucidation into the dependence on the physicochemical characteristics. J Control Release (2010) 0.97
Nanomedical engineering: shaping future nanomedicines. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2014) 0.89
Biological assessment of triazine dendrimer: toxicological profiles, solution behavior, biodistribution, drug release and efficacy in a PEGylated, paclitaxel construct. Mol Pharm (2010) 0.86
Clinically relevant anticancer polymer Paclitaxel therapeutics. Cancers (Basel) (2010) 0.84
A phase I study with MAG-camptothecin intravenously administered weekly for 3 weeks in a 4-week cycle in adult patients with solid tumours. Br J Cancer (2004) 0.82
Cathepsin B-cleavable doxorubicin prodrugs for targeted cancer therapy (Review). Int J Oncol (2012) 0.82
Nanoparticle-mediated drug delivery for treating melanoma. Nanomedicine (Lond) (2015) 0.79
Improving aqueous solubility and antitumor effects by nanosized gambogic acid-mPEG₂₀₀₀ micelles. Int J Nanomedicine (2013) 0.79
Biodegradable multiblock poly(N-2-hydroxypropyl)methacrylamide gemcitabine and paclitaxel conjugates for ovarian cancer cell combination treatment. Int J Pharm (2013) 0.78
Noninvasive detection of passively targeted poly(ethylene glycol) nanocarriers in tumors. Mol Pharm (2011) 0.78
Solid-nanoemulsion preconcentrate for oral delivery of paclitaxel: formulation design, biodistribution, and γ scintigraphy imaging. Biomed Res Int (2014) 0.76
Indium-based and iodine-based labeling of HPMA copolymer-epirubicin conjugates: Impact of structure on the in vivo fate. J Control Release (2016) 0.75
In vitro and in vivo targeting effect of folate decorated paclitaxel loaded PLA-TPGS nanoparticles. Saudi Pharm J (2015) 0.75
Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell (1994) 6.02
Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res (2001) 4.05
Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci U S A (1997) 2.91
Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. J Clin Oncol (2002) 2.90
Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J Natl Cancer Inst (2000) 2.73
Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J Clin Oncol (1997) 2.29
High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals. AIDS (2001) 2.03
Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res (1999) 2.00
European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol (1994) 1.97
Telephone-based nursing intervention improves the effectiveness of the informed consent process in cancer clinical trials. J Clin Oncol (1996) 1.95
Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL. Cancer Res (1996) 1.95
Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. Proc Natl Acad Sci U S A (2000) 1.83
Relationship between exposure and toxicity in high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin. Ann Oncol (2002) 1.78
Randomised trial comparing two combination chemotherapy regimens (Hexa-CAF vs CHAP-5) in advanced ovarian carcinoma. Lancet (1984) 1.77
Increased sensitivity to anticancer drugs and decreased inflammatory response in mice lacking the multidrug resistance-associated protein. Nat Med (1997) 1.75
Survival after massive ecstasy overdose. J Toxicol Clin Toxicol (1998) 1.75
Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel. J Clin Oncol (2001) 1.70
Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis. Eur J Cancer (2001) 1.65
Weekly oral paclitaxel as first-line treatment in patients with advanced gastric cancer. Ann Oncol (2003) 1.65
Taxanes: a new class of antitumor agents. Cancer Invest (1995) 1.62
The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in human immunodeficiency virus type 1-infected persons. J Infect Dis (2001) 1.62
EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC Early Clinical Studies Group. Eur J Cancer (1996) 1.58
The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals. AIDS (2000) 1.56
A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin) Clin Cancer Res (1999) 1.54
Long-term follow-up of non-seminomatous testicular cancer patients with mature teratoma or carcinoma at postchemotherapy surgery. EORTC Genitourinary Tract Cancer Cooperative Group (EORTC GU Group) Eur J Cancer (1991) 1.52
Phase I study on docetaxel and ifosfamide in patients with advanced solid tumours. Br J Cancer (1998) 1.51
Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. J Clin Oncol (1993) 1.51
Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer. J Clin Oncol (1999) 1.48
Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833. J Clin Invest (1997) 1.48
Preparation and stability testing of a hydrogel for topical analgesia. Pharm World Sci (1995) 1.47
Extensive cytoreductive surgery followed by intra-operative hyperthermic intraperitoneal chemotherapy with mitomycin-C in patients with peritoneal carcinomatosis of colorectal origin. Eur J Cancer (2001) 1.45
Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdr 1a P-glycoprotein. Br J Pharmacol (1996) 1.45
Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients. Br J Cancer (1999) 1.45
Long-term survival in ovarian cancer. Mature data from The Netherlands Joint Study Group for Ovarian Cancer. Eur J Cancer (1991) 1.44
Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer. J Clin Oncol (1999) 1.43
Thiopurine metabolism and identification of the thiopurine metabolites transported by MRP4 and MRP5 overexpressed in human embryonic kidney cells. Mol Pharmacol (2002) 1.42
Lithium pharmacokinetics during cisplatin-based chemotherapy: a case report. Cancer Chemother Pharmacol (1994) 1.40
Quantification of cabazitaxel, its metabolite docetaxel and the determination of the demethylated metabolites RPR112698 and RPR123142 as docetaxel equivalents in human plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2013) 1.40
[Severe phenytoin intoxication in patients with hypoalbuminaemia]. Ned Tijdschr Geneeskd (2007) 1.40
[Pleurodesis in malignant pleural effusion]. Ned Tijdschr Geneeskd (1997) 1.39
A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours. Br J Cancer (2012) 1.38
Systematic study on the chemical stability of the prodrug antitumor agent carzelesin (U-80,244) J Pharm Sci (1996) 1.38
Randomized trial of Cervene, a kappa receptor-selective opioid antagonist, in acute ischemic stroke. J Stroke Cerebrovasc Dis (2007) 1.37
Steady-state pharmacokinetics of twice-daily dosing of saquinavir plus ritonavir in HIV-1-infected individuals. J Acquir Immune Defic Syndr (2001) 1.37
Malignant effusions contain lysophosphatidic acid (LPA)-like activity. Ann Oncol (1998) 1.35
Quantitative analysis of gemcitabine triphosphate in human peripheral blood mononuclear cells using weak anion-exchange liquid chromatography coupled with tandem mass spectrometry. J Mass Spectrom (2006) 1.34
Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma. J Clin Oncol (1987) 1.34
Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors. J Clin Oncol (2001) 1.33
Synovial macrophage depletion with clodronate-containing liposomes in rheumatoid arthritis. Arthritis Rheum (2000) 1.32
Characterization of drug transport by the human multidrug resistance protein 3 (ABCC3). J Biol Chem (2001) 1.31
P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir. Mol Pharmacol (2001) 1.30
Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours. Eur J Cancer (2002) 1.30
Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918. Clin Cancer Res (2001) 1.29
Approaching tumour therapy beyond platinum drugs: status of the art and perspectives of ruthenium drug candidates. J Inorg Biochem (2011) 1.29
Antiretroviral drugs and the central nervous system. AIDS (1998) 1.28
Carcinogen and anticancer drug transport by Mrp2 in vivo: studies using Mrp2 (Abcc2) knockout mice. J Pharmacol Exp Ther (2006) 1.27
Tissue distribution, metabolism and excretion of paclitaxel in mice. Anticancer Drugs (1996) 1.27
Pharmacokinetic parameters of nevirapine and efavirenz in relation to antiretroviral efficacy. AIDS Res Hum Retroviruses (2006) 1.26
Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. The European Cancer Centre. J Clin Oncol (1997) 1.25
Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience. Antivir Ther (2001) 1.24
Penetration of zidovudine into the cerebrospinal fluid of patients infected with HIV. AIDS (1993) 1.23
The role of nuclear receptors in pharmacokinetic drug-drug interactions in oncology. Cancer Treat Rev (2007) 1.23
Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a phase I study. Clin Cancer Res (1997) 1.22
Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol (2002) 1.22
Breast cancer resistance protein is localized at the plasma membrane in mitoxantrone- and topotecan-resistant cell lines. Cancer Res (2000) 1.21
Altered pharmacokinetics of vinblastine in Mdr1a P-glycoprotein-deficient Mice. J Natl Cancer Inst (1996) 1.21
Influence of dose and infusion duration on pharmacokinetics of ifosfamide and metabolites. Drug Metab Dispos (2001) 1.20
Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients. Br J Clin Pharmacol (2006) 1.20
Complete remission at laparotomy: still a gold standard in ovarian cancer? Lancet (1986) 1.16
High exposures to bioactivated cyclophosphamide are related to the occurrence of veno-occlusive disease of the liver following high-dose chemotherapy. Br J Cancer (2006) 1.16
Morphine tissue levels and reduction of gastrointestinal transit in rats. Correlation supports primary action site in the gut. Gastroenterology (1983) 1.16
Ras biochemistry and farnesyl transferase inhibitors: a literature survey. Anticancer Drugs (2001) 1.16
PXR-mediated induction of P-glycoprotein by anticancer drugs in a human colon adenocarcinoma-derived cell line. Cancer Chemother Pharmacol (2009) 1.16